Robert Naismith is a Multiple Sclerosis Research Studies physician affiliated with Washington University in St. Louis. OpenAlex indexes 532 publications with 7,926 citations (h-index 50); ClinicalTrials.gov lists 1 registered study with this person as an investigator.
Data verified 14 Aug 2026
Overview
Updated 1 Sept 2026
Robert Naismith, MD, is affiliated with Washington University in St. Louis. The public record shows 532 publications with 7,926 citations (h-index 50), centered on Multiple Sclerosis Research Studies, Peripheral Neuropathies and Disorders, Polyomavirus and related diseases. It also documents an investigator role on 1 registered clinical trials, industry payments reported by 27 companies, 2 NIH-funded awards (2007–2015).
- Most recent indexed publication: 2026 · Neurology and therapy
- Top research focus: Multiple Sclerosis Research Studies
- 1 registered trials on ClinicalTrials.gov
- Open Payments reporting from 27 companies
Generated from the cited public record · current as of 1 Sept 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 14 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 109.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 1 Sept 2026
Listed as an investigator on 1 registered study on ClinicalTrials.gov. The most recent:
- Ampyra for Optic Neuritis in Multiple Sclerosis
Sponsor: Washington University School of Medicine
Industry payments
Updated 1 Sept 2026
27 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- SANOFI-AVENTIS U.S. LLCProgram year202516 payments$72,450openpaymentsdata.cms.gov ↗
- GENZYME CORPORATIONProgram year202518 payments$38,061openpaymentsdata.cms.gov ↗
- E.R. Squibb & Sons, L.L.C.Program year20254 payments$10,503openpaymentsdata.cms.gov ↗
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
48.8%Gabapentinoids14.9%Gabapentin80%Pregabalin21%Part D<11 patientsSSRI10.2%Trazodone Hcl40%Paroxetine Hcl21%Fluoxetine Hcl20%Sertraline Hcl20%Part D<11 patientsCancer & immunology
28.1%Pyrimidine Synthesis Inhibitor7%Teriflunomide71%Aubagio29%Part D<11 patientsInterferon beta5.6%Avonex Pen (4 Pack)46%Rebif Rebidose34%Avonex (4 Pack)20%Part D<11 patientsMusculoskeletal
13.6%gamma-Aminobutyric Acid-ergic Agonist8.7%Baclofen100%Part D≥27 patientsMuscle Relaxant2.5%Cyclobenzaprine Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 1 Sept 2026
2 NIH research awards on record, funded 2007–2015 per NIH RePORTER. The latest:
- Novel non-narcotic analgesic for acute and chronic pain
South Rampart Pharma, Llc
FY2023$399,539SB1NS119103 - NONINVASIVELY DISTINGUISHING INFLAMMATION FROM TISSUE INJURY IN OPTIC NEURITIS
Washington University
FY2015$194,284R21NS090910 - NONINVASIVELY DISTINGUISHING INFLAMMATION FROM TISSUE INJURY IN OPTIC NEURITIS
Washington University
FY2014$245,534R21NS090910
Publications
Updated 1 Sept 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Safety and efficacy of opicinumab in participants with relapsing multiple sclerosis (AFFINITY Part 1): A randomized, controlled, phase 2 trial.
Multiple sclerosis (Houndmills, Basingstoke, England)
Clinical Trial2026 - Randomised controlled trial of intermittent calorie restriction in people with multiple sclerosis.
Journal of neurology, neurosurgery, and psychiatry
Clinical Trial2025
Most-cited works
by citation count (OpenAlex)- 01Radial diffusivity predicts demyelination in ex vivo multiple sclerosis spinal cordsArticle366 citations2011
- 02The contemporary spectrum of multiple sclerosis misdiagnosisArticle326 citations2016
- 03
- 04Phase 2 Trial of Ibudilast in Progressive Multiple SclerosisArticle288 citations2018
- 05
Network
Updated 1 Sept 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 1 Sept 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/robert-naismith-md-e06895bc
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Timothy Ley, MD
Washington University in St. Louis
David Gutmann, MD
Washington University in St. Louis
Randall Bateman, MD
Washington University in St. Louis
Victoria Fraser, MD
Washington University in St. Louis